BAMCO Inc
ALXN

BAMCO Inc’s Alexion Pharmaceuticals ALXN Stock Holding History

BAMCO Inc’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-20,470
Closed -$2.5M – 339
2016
Q4 		$2.5M Sell
20,470
-23,790
-54% -$2.91M 0.01% 241
2016
Q3 		$5.42M Sell
44,260
-17,989
-29% -$2.32M 0.03% 212
2016
Q2 		$7.27M Buy
62,249
+6,299
+11% +$894K 0.04% 197
2016
Q1 		$7.79M Sell
55,950
-5,227
-9% -$767K 0.04% 199
2015
Q4 		$11.7M Buy
61,177
+28,553
+88% +$4.99M 0.05% 206
2015
Q3 		$5.1M Sell
32,624
-37,140
-53% -$6.77M 0.02% 241
2015
Q2 		$12.6M Buy
69,764
+28,601
+69% +$4.94M 0.05% 229
2015
Q1 		$7.13M Buy
41,163
+22,797
+124% +$4.13M 0.03% 255
2014
Q4 		$3.4M Buy
18,366
+5,425
+42% +$1.01M 0.01% 274
2014
Q3 		$2.15M Buy
12,941
+2,796
+28% +$459K 0.01% 289
2014
Q2 		$1.58M Sell
10,145
-73
-0.7% -$11.5K 0.01% 297
2014
Q1 		$1.55M Buy
+10,218
New +$1.62M 0.01% 293

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BAMCO Inc's ALXN Position: Q1 2017 in Review

BAMCO Inc sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 20,470 shares — an estimated $2.5M sold.

BAMCO Inc first reported a position in ALXN in Q1 2014 and held it in 12 quarters. The position peaked at $12.6M in Q2 2015. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • BAMCO Inc reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • BAMCO Inc sold 20,470 Alexion Pharmaceuticals shares in Q1 2017, an estimated $2.5M.
  • BAMCO Inc first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 12 quarters.
  • BAMCO Inc's Alexion Pharmaceuticals position peaked at $12.6M in Q2 2015.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on BAMCO Inc's 13F filing for Q1 2017, filed 15 May 2017.